Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been here as long if not longer than you. I don’t bash a company I hold stock in on message boards really is not point. You don’t seem to be interested in acknowledging some of the positive moves made by management only the negative.
I fully agree they need to be more proactive with shareholders and that was pretty much acknowledged when I spoke with IR. There maybe reasons why, but if I am right this will change after Q results are out.
Look Capt and Cabin, I can agree with you that company needs to be more vocal with shareholders, but if you really do hold stock you have to acknowledge that company is in a much better place than it was. No toxic debt, no other debt, cash in the bank and growing.
You don’t bash a stock you hold to the degree you do if you hold. Yes they need to be more proactive but they have made some positive moves.
Even filings today, maybe director is being paid for his services in shares rather than cash, if so that’s a good thing if he wants shares rather than cash.
Looks like cabin has joined the capt camp, slates the stock but maintains he holds many shares.
Just so people know who DR Rodriguez is, and the fact he is an independant director at RXMD. It’s like it’s never been heard of that a Director get shares, maybe rather than any pay for being a director at a company.
Dr. Rodriguez is a medical professional with over 40 years of experience in the psychiatry field. Currently, Dr. Rodriguez is the Chairman and Medical Director of the Department of Psychiatry at Mount Sinai Medical Center in Miami Beach, FL. Previously, Dr. Rodriguez was the Chairman and Medical Director of the Department of Psychiatry at Cedar’s Medical Center in Miami, FL from 1993-2003. Dr. Rodriguez is a Diplomat in the Specialty of Psychiatry in the American Board of Psychiatry and Neurology and is a member of the State of Florida Board of Medical Examiners. Dr. Rodriguez has been the recipient of numerous awards and recognized in the Miami community as one of the Community’s most eminent physicians. Dr. Rodriguez received his doctorate degree from the University of Salamanca School of Medicine and an MBA from the University of Miami Herbert Business School.
For information, my impression is that company is fully aware that it needs to update shareholders and that after Q results we should get a more regular flow of news.
Also seems that business is still moving in right direction with several potential revenue streams coming on line.
My impression and opinion is that Q results will be good.
I just emailed him and he set up a time to talk
For info I had long conversation with the IR guy for NXPL and RXMD. I was happy with our discussion and if anybody has any questions I suggest you contact him direct.
Form 4’s just showed up, NXPL and insiders hold alot of shares.
Thanks stock, you do provide valuable info.
But you bash a company you say you hold and don’t acknowledge that fundamentally the company is in a much better place than it was.
No debt
$7 million + in the bank probably $8 million plus now.
Increasing revenue especially in its high margin growth side.
Not always does share price match with business, but at some point it will.
Personally I believe the reason for it being so quiet is;
NXPL waiting to close sale of its core business.
NXPL and RXMD will then merge.
Will use all that cash on hand to invest in additional medical business to drive growth.
It’s difficult to deny that the business is growing in the right direction. And the more profitable side of the business is growing and a much faster rate;
“The Company recorded the highest level of income from operations in recent history of $0.6 million during the second quarter of 2023, an increase of $0.8 million when compared to the prior year period.
Gross profit margin increased to 31% from 20% reported in the second quarter of 2022 primarily due to the increase in 340B contract revenue which has higher margins than revenue generated from pharmacy operations.”
The only thing I can agree on with what’s being said is that it would be nice to have so communication from the company.
Totally wrong, I fully expect a profit to be shown and a good one at that. I have no idea how accounting rules work behind the scene as shown in last Q, which would have shown a profit. I don’t expect those rules to be there this time.
If you look at this from last Q, the high margin areas will be what drives profitability this Q and many Q to come. It will take some to realize it but when they do we will be golden.
“The Company recorded the highest level of income from operations in recent history of $0.6 million during the second quarter of 2023, an increase of $0.8 million when compared to the prior year period.
Gross profit margin increased to 31% from 20% reported in the second quarter of 2022 primarily due to the increase in 340B contract revenue which has higher margins than revenue generated from pharmacy operations.”
Unless there are any accounting write offs then I would be shocked if we don’t show a decent profit this Q.
Let’s not forget that $7 million must be paying some pretty good interest.
Company did the right thing, they combined several positions to save cash on both sides, ie CFO role. Pretty sure many would be ranting if they had not done that.
Profit margins will drive this, and that’s where company is focused, healthcare data management.
I think it’s pretty clear that their focus is on healthcare, and I expect this Q for RXMD to show a healthy increase in profitability.
As long as numbers continue to trend higher which I think they will significantly,then at some point market will react.
The only thing I can agree on is that it would be nice if company was not so silent and let us know what the master plan is, because I am sure they have one.
Most important thing for me is that we continue to see growth in high margin areas. company has done a pretty good job and i expect this to continue, next Q results should be pretty telling.
Eventually share price will reflect growth.
COCONUT GROVE and MIAMI, FL / ACCESSWIRE / October 12, 2023 / NextPlat Corp (NASDAQ:NXPL)(NASDAQ:NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health, Inc. (NASDAQ: OPK) products in China. Under the terms of the agreement, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited's (BABA) ("Alibaba") Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe.
OPKO is a global diversified diagnostic and pharmaceutical healthcare company with over 5,500 employees spanning nine countries. The distribution agreement with OPKO's European division represents the first relationship resulting from the Company's Florida E-commerce Development program which includes a merchant sourcing agreement with Alibaba's Tmall Global designed to provide American businesses with easy access to the Chinese consumer market.
"NextPlat's focus is to enable companies across an array of high-growth sectors such as healthcare and consumer products, to capitalize on the vast opportunities of global e-commerce. Having already successfully built a sizable portfolio of products for human and animal health, we believe OPKO Europe is an ideal customer for our new e-commerce development program. By leveraging our online expertise, capabilities, and our expanded relationship with Alibaba, we can uniquely provide OPKO Europe with a reliable and efficient way to quickly begin selling its products online to potentially millions of new consumers in China," said Charles M. Fernandez, Executive Chairman and CEO of NextPlat.
COCONUT GROVE and MIAMI, FL / ACCESSWIRE / October 12, 2023 / NextPlat Corp (NASDAQ:NXPL)(NASDAQ:NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health, Inc. (NASDAQ: OPK) products in China. Under the terms of the agreement, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited's (BABA) ("Alibaba") Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe.
OPKO is a global diversified diagnostic and pharmaceutical healthcare company with over 5,500 employees spanning nine countries. The distribution agreement with OPKO's European division represents the first relationship resulting from the Company's Florida E-commerce Development program which includes a merchant sourcing agreement with Alibaba's Tmall Global designed to provide American businesses with easy access to the Chinese consumer market.
"NextPlat's focus is to enable companies across an array of high-growth sectors such as healthcare and consumer products, to capitalize on the vast opportunities of global e-commerce. Having already successfully built a sizable portfolio of products for human and animal health, we believe OPKO Europe is an ideal customer for our new e-commerce development program. By leveraging our online expertise, capabilities, and our expanded relationship with Alibaba, we can uniquely provide OPKO Europe with a reliable and efficient way to quickly begin selling its products online to potentially millions of new consumers in China," said Charles M. Fernandez, Executive Chairman and CEO of NextPlat.
Could just be some anticipation brewing over at NXPL in relation to presentation on the 12th. Been sometime since CEO or anybody at company said anything, let’s hope things are about to change. RXMD is the future of NXPL so I expect them to talk about healthcare a lot.
NXPL shares up again today.
NXPL on the move today
Maybe the quiet lid is going to be blown off and we start to hear the plan, no point presenting if you have nothing to say.
Agree no doubt healthcare is their focus.
No idea, especially as we could get news at anytime, Tom did say they would file either late this week or early next week.
Stock, no doubt company has the talent and the right connections to move forward on all fronts, just need that update to let us know what the plan is.
Just added more myself, FDA filing anyway now
Thought this was interesting from page 2;
PharmcoRx is powered by Nextplat's technology ecosystem to provide state-of-the-art solutions for medical offices.
Nice, now he is going to know a lot of people.
NXPL just issued 8K;
Item 2.01. Completion of Acquisition or Disposition of Assets
As previously disclosed, NextPlat Corp (the "Company") has made a series of investments in Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care") beginning with an initial investment that closed on September 2, 2022.
On July 1, 2023, each of the Company, Charles M. Fernandez, and Rodney Barreto exercised common stock purchase warrants and were issued common stock shares from Progressive Care. The Company exercised common stock warrants on a cashless basis and received 402,269 shares of Progressive Care common stock. The Company also exercised common stock warrants on a cash basis and paid consideration in the amount of $506,000 in return for 230,000 shares of Progressive Care common stock. Mr. Fernandez exercised common stock warrants on a cashless basis and received 211,470 shares of Progressive care common stock. Mr. Barreto exercised common stock warrants on a cashless basis and received 130,571 shares of Progressive Care common stock. After these warrant exercises, the aggregate number of shares of Progressive Care common stock owned by the Company, Mr. Fernandez, and Mr. Barreto represent 53% of Progressive Care’s issued and outstanding common stock.
On June 30, 2023, the Company entered into a voting agreement with Messrs. Fernandez and Barreto pursuant to which Messrs. Fernandez and Barreto agreed to vote all of their shares of Progressive Care common stock (whether owned directly or indirectly) in the same manner that the Company votes its shares of Progressive Care common stock at any annual or special shareholders meeting of the stockholders of Progressive Care, and whenever the holders of Progressive Care’s common stock act by written consent. The voting agreement has a perpetual term.
As a result of the common stock warrant purchases and the entry into the voting agreement, the Company concluded that there was a change in control of Progressive Care with the Company having the right to control more than 50 percent of the voting interests in Progressive Care as of July 1, 2023 through the concurrent warrant exercises and voting agreement noted above.
As a result of the change in control of Progressive Care, the Company is filing this report to provide the financial statements and pro forma financial information required by Items 9.01(a) and 9.01(b) of Form 8-K, respectively.
Agree but somebody is nibbling.
Personally I think there is someone in the background slowly adding, but not wanting to be aggressive that causes the ask to rise.
Would love to see an insider purchase show up.
That happened to me a few weeks back, got some cheaper than I was willing to pay.
I think if we can break through this $6, which we have tested a few times then we will move up nicely.
Just need some news to get some volume and we get a major pop. Certainly good to see bid growing.
Certainly no reason to sell, just got to look at past history to see this will run upto FDA news, and this time it looks like company has completed everything and more FDA requested.
Some weird trades showing up today, several high ask buys immediately followed by lower ask buys to keep the price down.
While we wait I would suggest you take a look at RMSL, my second biggest holding behind RXMD. Put Tweet out this morning re all tests passed for their Deltawave mask, and submission to FDA within 2-4 weeks. I can tell you know that on submission news this will go up, and you are looking at 90 to 120 days for approval. Stock will as before creep up from now until submission and then as it gets closer to FDA timeline.
I have no doubt things will move in the right direction, and when I saw that Dr Frost had invested I added. Would just be nice to get an update.
Stock, I thinks it’s pretty clear that NXPL are going all in on healthcare. Only thing I agree on that Capt says is that we need them to update us all on the plan going forward.
We know RXMD business is growing, what’s the plan to accelerate that growth.